• Profile
Close

A randomized trial investigating the pharmacokinetics, pharmacodynamics, and safety of subcutaneous semaglutide once-weekly in healthy male Japanese and Caucasian subjects

Advances in Therapy Mar 21, 2018

Ikushima I, et al. - A comparative scrutiny was performed of the pharmacokinetics, pharmacodynamics, and safety of semaglutide in Japanese and Caucasian individuals for the treatment of type 2 diabetes. Findings revealed similar pharmacokinetic, pharmacodynamic, and safety profiles of semaglutide among Japanese and Caucasian subjects. Yielded data indicated that no dose adjustment was needed for the clinical use of semaglutide in Japanese subjects.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay